Updated:
Nippon Shinyaku
Nippon Shinyaku is a pension fund based in Kyoto, founded 1919; the Altss profile covers its classification, headquarters, registration, AUM band, and key...
Nippon Shinyaku
Nippon Shinyaku is a research-oriented pharmaceutical company dedicated to research and development of drugs.
General information
Firm type
Pension Fund
Year founded
1919
AUM
Undisclosed
Location
Region
Asia
Country
Japan
City
Kyoto
Corporate office
14, Nishinosho-Monguchi-cho, Kisshoin, Minami-ku, Kyoto, Japan
Additional offices
Paramus, New Jersey, USA
Principals
Shigenobu Maekawa
Chairman of the Board
Toru Nakai
Representative Director and President
Sector focus
Frequently asked questions
How is Nippon Shinyaku's pension fund structured?
The Nippon Shinyaku Corporate Pension Fund operates as a hybrid defined-benefit and defined-contribution cash-balance plan. Its investment strategy includes direct venture capital allocations alongside the parent pharmaceutical company's strategic initiatives.
Does the pension fund co-invest alongside Nippon Shinyaku's corporate partnerships?
Yes, the fund's venture capital deployment is closely aligned with the parent company's R&D collaborations. Strategic partners include Regenxbio Inc., with whom Nippon Shinyaku has a collaboration involving significant upfront equity and milestone commitments, and Eli Lilly Japan, a commercialization alliance partner.
What real assets does the Nippon Shinyaku pension fund hold?
The fund's parent company holds significant operational real estate that sits within its broader asset base, including the Odawara Central Factory, Discovery Research Laboratories in Tsukuba, and the Yamashina Botanical Research Institute in Kyoto. The US subsidiary NS Pharma operates from Paramus, New Jersey.
Who runs investment decisions at the Nippon Shinyaku corporate pension fund?
Governance ultimately flows through the parent company's leadership. Shigenobu Maekawa serves as Chairman of the Board and represents the founding family's influence, while Toru Nakai acts as Representative Director and President. Specific investment committee structures and dedicated pension CIO details are not publicly disclosed.
What is Nippon Shinyaku's known posture on external fund commitments?
The pension fund's disclosed strategy centers on venture capital allocations, and its parent company engages in direct strategic collaborations with biotech firms such as Regenxbio. Whether the fund also commits to external venture or private equity funds as a limited partner is not detailed in public records.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on pension funds?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: